Digital Media briefs: August 2012

Share this article:
Digital Media briefs: August 2012
Digital Media briefs: August 2012

The FDA granted 501(k) approval for iHealth's blue­tooth blood pressure monitor, which debuted at the June Pepcom Digital Experience. The device works in two ways: it has a wrist wrap instead of a bicep wrap and channels the reading to an app that can be used with iOS devices.

A study shows that smartphones are where the purchasing power is. According to research firm Deloitte, almost 50% of smartphone users say their phones helped them choose an item while bricks-and-mortar shopping, and more than 33% of the users used a smartphone shopping app to help them decide.

An eMarketer report forecasts US digital pharma and healthcare industry ad spend on paid media will grow at a compound annual rate of 14.1% between 2011 and 2016. But the end result—$2.48 billion by 2016, eMarketer predicted—means pharma will still be playing catch-up on digital.

Mobile use is rising, but a survey by Sharecare shows that most doctors don't use phones and tablets in clinical settings. The survey showed that about 12% of doctors used ­iPads and 9% use another type of tablet to input data, but that the rest are going old-school­—using desktops, and in lesser numbers, laptops.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro